Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery

The purpose of this study is to determine if the addition of bupivacaine HCl injections will improve pain control after skin surgery.

This is a randomized clinical trial. Approximately 100 participants will be randomized to receive either bupivacaine HCl or saline injections to help with the postsurgical pain. Patients will be provided with a take-home journal to complete indicating when and how much pain medication they required for the 3 days immediately following surgery. Participants will return the journal in-person at a follow up visit 7-21 days post-op. This study was a pilot study designed to determine the feasibility of this procedure.

Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be invited and considered for enrollment.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Pain, Postoperative Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Signs and Symptoms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Northwestern University Department of Dermatology

Chicago, Illinois, 60611, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

>18 years of age
Receiving cutaneous surgery
In good general health as assessed by the investigator

Exclusion criteria

Participants with an allergy to bupivacaine or other amide anesthetics
Participants unwilling to sign an IRB approved consent form
Participants with a contraindication to narcotic medication
Participants who are pregnant or will become pregnant
Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible

Treatment and study plan

Bupivacaine Hydrochloride

Drug

Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.

Saline

Drug

Normal saline injections.

Primary outcomes

Reported opioid and non-opioid pain medications taken

Time frame: 3 Days Post-Surgery

Patients will report the amount of pain medications taken 3 days immediately following surgery

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Official study title

Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: A Randomized Controlled Trial

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2028
First posted: Feb 7, 2020
Registry last updated: Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation